Curcumin C3 complex®/Bioperine® has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis.
Curcumin C3 complex
Intrinsic apoptosis
Mesothelioma
Tumor growth inhibition
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
16 Aug 2019
16 Aug 2019
Historique:
received:
30
05
2019
accepted:
08
08
2019
entrez:
18
8
2019
pubmed:
20
8
2019
medline:
11
2
2020
Statut:
epublish
Résumé
A major limitation in the treatment for malignant mesothelioma is related to serious side effects caused by chemotherapeutics and to the development of cancer-resistance. Advances in cancer therapies have been reached thanks to the introduction of alternative approaches, such as the use of phytochemicals. Curcumin-C3complex®/Bioperine® is a commercially standardized extract containing a ratio-defined mixture of three curcuminoids and piperine that greatly increase its bioavailability. Interestingly, the anticancer effect of this formulation has been described in different studies and several clinical trials have been started, but to our knowledge none refers to human mesothelioma. Curcumin-C3complex®/Bioperine® anticancer effect was evaluated in vitro in different human mesothelioma cell lines analysing cell proliferation, colony-forming assay, wound healing assays, invasion assay and FACS analysis. In vivo anticancer properties were analysed in a mesothelioma xenograft mouse model in CD1 Nude mice. Curcumin-C3complex®/Bioperine® in vitro induced growth inhibition in all mesothelioma cell lines analysed in a dose- and time-depended manner and reduced self-renewal cell migration and cell invasive ability. Cell death was due to apoptosis. The analysis of the molecular signalling pathway suggested that intrinsic apoptotic pathway is activated by this treatment. This treatment in vivo delayed the growth of the ectopic tumours in a mesothelioma xenograft mouse model. Curcumin-C3complex®/Bioperine® treatment strongly reduces in vitro tumorigenic properties of mesothelioma cells by impairing cellular self-renewal ability, proliferative cell rate and cell migration and delays tumor growth in xenograft mouse model by reducing angiogenesis and increasing apoptosis. Considering that curcumin in vivo synergizes drug effects, its administration to treatment regimen may help to enhance drug therapeutic efficacy in mesothelioma. Our results suggest that implementation of standard pharmacological therapies with novel compounds may pave the way to develop alternative approaches to mesothelioma.
Sections du résumé
BACKGROUND
BACKGROUND
A major limitation in the treatment for malignant mesothelioma is related to serious side effects caused by chemotherapeutics and to the development of cancer-resistance. Advances in cancer therapies have been reached thanks to the introduction of alternative approaches, such as the use of phytochemicals. Curcumin-C3complex®/Bioperine® is a commercially standardized extract containing a ratio-defined mixture of three curcuminoids and piperine that greatly increase its bioavailability. Interestingly, the anticancer effect of this formulation has been described in different studies and several clinical trials have been started, but to our knowledge none refers to human mesothelioma.
METHODS
METHODS
Curcumin-C3complex®/Bioperine® anticancer effect was evaluated in vitro in different human mesothelioma cell lines analysing cell proliferation, colony-forming assay, wound healing assays, invasion assay and FACS analysis. In vivo anticancer properties were analysed in a mesothelioma xenograft mouse model in CD1 Nude mice.
RESULTS
RESULTS
Curcumin-C3complex®/Bioperine® in vitro induced growth inhibition in all mesothelioma cell lines analysed in a dose- and time-depended manner and reduced self-renewal cell migration and cell invasive ability. Cell death was due to apoptosis. The analysis of the molecular signalling pathway suggested that intrinsic apoptotic pathway is activated by this treatment. This treatment in vivo delayed the growth of the ectopic tumours in a mesothelioma xenograft mouse model.
CONCLUSIONS
CONCLUSIONS
Curcumin-C3complex®/Bioperine® treatment strongly reduces in vitro tumorigenic properties of mesothelioma cells by impairing cellular self-renewal ability, proliferative cell rate and cell migration and delays tumor growth in xenograft mouse model by reducing angiogenesis and increasing apoptosis. Considering that curcumin in vivo synergizes drug effects, its administration to treatment regimen may help to enhance drug therapeutic efficacy in mesothelioma. Our results suggest that implementation of standard pharmacological therapies with novel compounds may pave the way to develop alternative approaches to mesothelioma.
Identifiants
pubmed: 31419989
doi: 10.1186/s13046-019-1368-8
pii: 10.1186/s13046-019-1368-8
pmc: PMC6698046
doi:
Substances chimiques
Antineoplastic Agents
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
360Références
Immunol Cell Biol. 1999 Aug;77(4):312-7
pubmed: 10457197
Cell Death Differ. 2003 Jan;10(1):36-44
pubmed: 12655294
Cell Death Differ. 2003 Jan;10(1):76-100
pubmed: 12655297
J Biol Chem. 2005 Jul 1;280(26):25284-90
pubmed: 15879598
Mol Cell Biochem. 2007 Feb;296(1-2):85-95
pubmed: 16960658
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6133-43
pubmed: 17062690
Cancer Res. 2007 Jan 1;67(1):362-70
pubmed: 17210719
J Biol Chem. 2007 Jun 1;282(22):15954-64
pubmed: 17392282
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
J Exp Clin Cancer Res. 2007 Dec;26(4):443-9
pubmed: 18365537
Curr Opin Pulm Med. 2008 Jul;14(4):303-9
pubmed: 18520263
J Exp Clin Cancer Res. 2008 May 19;27:6
pubmed: 18577247
PLoS One. 2009 Sep 15;4(9):e7016
pubmed: 19753302
Int J Cancer. 2011 Jul 15;129(2):476-86
pubmed: 20839263
Methods Mol Biol. 2011;708:213-28
pubmed: 21207293
Mol Cell Biochem. 2011 Nov;357(1-2):83-94
pubmed: 21594647
PLoS One. 2011;6(8):e23569
pubmed: 21858171
Eukaryot Cell. 2011 Nov;10(11):1574-81
pubmed: 21908599
Panminerva Med. 2011 Sep;53(3 Suppl 1):43-9
pubmed: 22108476
Cancer Prev Res (Phila). 2013 Feb;6(2):119-28
pubmed: 23233733
Cancer Lett. 2014 May 1;346(2):197-205
pubmed: 24463298
J Exp Clin Cancer Res. 2014 Mar 05;33:24
pubmed: 24598211
Anticancer Agents Med Chem. 2015;15(4):408-22
pubmed: 25584691
Carcinogenesis. 2015 Mar;36(3):355-67
pubmed: 25653233
Eur J Pharm Biopharm. 2015 Jun;93:37-45
pubmed: 25794477
Trials. 2015 Mar 24;16:110
pubmed: 25872567
Cancer Lett. 2015 Aug 10;364(2):135-41
pubmed: 25979230
Br J Cancer. 2015 Nov 17;113(10):1434-44
pubmed: 26469832
J Control Release. 2016 Jul 10;233:88-100
pubmed: 27155364
Oncotarget. 2016 Dec 27;7(52):86374-86387
pubmed: 27863439
Colloids Surf B Biointerfaces. 2017 Feb 1;150:223-241
pubmed: 27918967
J Med Chem. 2017 Mar 9;60(5):1620-1637
pubmed: 28074653
Int J Pharm. 2017 Mar 30;520(1-2):21-28
pubmed: 28130197
Oncotarget. 2017 May 23;8(21):34405-34422
pubmed: 28159921
Biochem Biophys Res Commun. 2018 May 27;500(1):26-34
pubmed: 28676391
Oncotarget. 2017 Feb 25;8(34):57552-57573
pubmed: 28915695
J Exp Clin Cancer Res. 2017 Dec 22;36(1):190
pubmed: 29273065
Int J Oncol. 2018 Dec;53(6):2531-2541
pubmed: 30272283
Transl Lung Cancer Res. 2018 Oct;7(5):599-608
pubmed: 30450299
Planta Med. 1998 May;64(4):353-6
pubmed: 9619120